Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

1.4K
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
1.4K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

13.5K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
13.5K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

675
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
675
Inflammatory Response01:28

Inflammatory Response

17.7K
An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
17.7K
Methods of reducing fever01:22

Methods of reducing fever

1.5K
The signs and symptoms of fever include hot and dry skin, flushed face, thirst, muscle aches, anorexia, headache, tachycardia, tachypnea, and fatigue. Elevated body temperature is reduced using two methods: pharmacological and nonpharmacological. Proper identification and treatment of the root cause of a fever is of utmost importance.
Pharmacological Methods of Reducing Fever:
1.5K
Adrenergic Agonists: Therapeutic Uses01:30

Adrenergic Agonists: Therapeutic Uses

2.1K
Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
2.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Summary of the update to the S3 guideline: Epidemiology, diagnosis and treatment of adult patients with nosocomial pneumonia].

Pneumologie (Stuttgart, Germany)·2025
Same author

[S3 guideline on sepsis-prevention, diagnosis, therapy, and follow-up care-update 2025].

Medizinische Klinik, Intensivmedizin und Notfallmedizin·2025
Same author

[Epidemiology, diagnosis and treatment of adult patients with nosocomial pneumonia].

Pneumologie (Stuttgart, Germany)·2025
Same author

Key summary of German national guideline for adult patients with nosocomial pneumonia- Update 2024 Funding number at the Federal Joint Committee (G-BA): 01VSF22007.

Infection·2024
Same author

A multifaceted educational intervention improved anti-infectious measures but had no effect on mortality in patients with severe sepsis.

Scientific reports·2022
Same author

Adverse effects of delayed antimicrobial treatment and surgical source control in adults with sepsis: results of a planned secondary analysis of a cluster-randomized controlled trial.

Critical care (London, England)·2022

Related Experiment Video

Updated: Mar 8, 2026

Author Spotlight: Unveiling the Polyfunctionality and Heterogeneity in Immune Responses
09:43

Author Spotlight: Unveiling the Polyfunctionality and Heterogeneity in Immune Responses

Published on: March 8, 2024

2.5K

Agents to reduce cytokine storm.

Herwig Gerlach1

  • 1Department of Anesthesia, Critical Care Medicine, and Pain Management, Vivantes - Klinikum Neukoelln, Klinik fuer Anaesthesie, operative Intensivmedizin und Schmerztherapie, Berlin, Germany.

F1000Research
|January 21, 2017
PubMed
Summary

Cytokine storm, a dysregulated host response, involves direct toxic and indirect immunomodulatory effects. This review summarizes therapeutic strategies for hyperinflammation in adult patients, primarily those with septic shock.

Keywords:
cytokine stormhyperinflammationsepsisseptic shock

More Related Videos

Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety
06:37

Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety

Published on: September 15, 2023

1.2K
Microbioreactor-Based Production of Anchorage-Dependent Mesenchymal Stromal Cells Primed for Acute Respiratory Distress Syndrome
09:06

Microbioreactor-Based Production of Anchorage-Dependent Mesenchymal Stromal Cells Primed for Acute Respiratory Distress Syndrome

Published on: December 12, 2025

791

Related Experiment Videos

Last Updated: Mar 8, 2026

Author Spotlight: Unveiling the Polyfunctionality and Heterogeneity in Immune Responses
09:43

Author Spotlight: Unveiling the Polyfunctionality and Heterogeneity in Immune Responses

Published on: March 8, 2024

2.5K
Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety
06:37

Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety

Published on: September 15, 2023

1.2K
Microbioreactor-Based Production of Anchorage-Dependent Mesenchymal Stromal Cells Primed for Acute Respiratory Distress Syndrome
09:06

Microbioreactor-Based Production of Anchorage-Dependent Mesenchymal Stromal Cells Primed for Acute Respiratory Distress Syndrome

Published on: December 12, 2025

791

Area of Science:

  • Immunology
  • Critical Care Medicine

Background:

  • The term "cytokine storm" emerged over 20 years ago due to insights into pathomechanisms of dysregulated host responses in inflammatory diseases.
  • Cytokine storms involve direct toxic effects and indirect immunomodulatory mechanisms, justifying interventions in hyperinflammatory states and life-threatening infections.

Purpose of the Study:

  • To review the background, pathophysiology, and clinical investigation results related to therapeutic strategies for cytokine storm syndromes.
  • To provide insights for developing international guidelines for managing hyperinflammation in adult patients, particularly in septic shock.

Main Methods:

  • Literature review of clinical investigations and trials.
  • Focus on studies related to sepsis and septic shock management.

Main Results:

  • Numerous clinical trials, mostly investigator-initiated, have explored treatments for cytokine storm.
  • Major trials have concentrated on sepsis and septic shock, informing therapeutic development.

Conclusions:

  • Understanding cytokine storm pathophysiology is crucial for developing effective therapeutic strategies.
  • Clinical investigations have laid the groundwork for international guidelines in managing hyperinflammation during cytokine storm syndromes.